Literature DB >> 6361374

Neonatal infection with the Daniels strain of Theiler's murine encephalomyelitis virus.

M Rodriguez, J L Leibowitz, H C Powell, P W Lampert.   

Abstract

The clinical and pathologic manifestation of Theiler's murine encephalomyelitis are age related. Animals infected during the first week of life die of a fulminant encephalitis analogous to human poliomyelitis. By contrast, animals infected within 2 and 4 weeks of age survive but develop chronic relapsing demyelination and persistent infection of the central nervous system. The neonatal infection results in widespread necrosis beginning with neuronal vacuolar degeneration followed by inflammatory infiltrates. Electron microscopy reveals paracrystalline arrays of 27-nm viral particles characteristic of picornaviruses within neurons and macrophages. In addition, oligodendrocytes show reactive changes and intracytoplasmic vacuoles. Immunoperoxidase studies show viral antigen primarily localized within neurons of the cerebral cortex, basal ganglia, hippocampus, and anterior horn cells. Viral antigen is found within the apical dendrites and axonal projections of hippocampal pyramidal cells suggesting that Theiler's murine encephalomyelitis may travel intraaxonally.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6361374

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  26 in total

1.  The relationship between viral RNA, myelin-specific mRNAs, and demyelination in central nervous system disease during Theiler's virus infection.

Authors:  M Yamada; A Zurbriggen; R S Fujinami
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

2.  Perforin-dependent neurologic injury in a viral model of multiple sclerosis.

Authors:  P D Murray; D B McGavern; X Lin; M K Njenga; J Leibowitz; L R Pease; M Rodriguez
Journal:  J Neurosci       Date:  1998-09-15       Impact factor: 6.167

3.  The immune system preferentially clears Theiler's virus from the gray matter of the central nervous system.

Authors:  M K Njenga; K Asakura; S F Hunter; P Wettstein; L R Pease; M Rodriguez
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Receptors for Theiler's murine encephalomyelitis virus: characterization by using rabbit antiviral antiserum.

Authors:  N Rubio; A Cuesta
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

5.  Neuropathogenesis of Zika Virus Infection : Potential Roles of Antibody-Mediated Pathology.

Authors:  Ikuo Tsunoda; Seiichi Omura; Fumitaka Sato; Susumu Kusunoki; Mitsugu Fujita; Ah-Mee Park; Faris Hasanovic; Richard Yanagihara; Satoshi Nagata
Journal:  Acta Med Kinki Univ       Date:  2016

6.  Major histocompatibility complex-conferred resistance to Theiler's virus-induced demyelinating disease is inherited as a dominant trait in B10 congenic mice.

Authors:  A K Patick; L R Pease; C S David; M Rodriguez
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

7.  Mode of spread to and within the central nervous system after oral infection of neonatal mice with the DA strain of Theiler's murine encephalomyelitis virus.

Authors:  Y M Ha-Lee; K Dillon; B Kosaras; R Sidman; P Revell; R Fujinami; M Chow
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Gamma interferon is critical for resistance to Theiler's virus-induced demyelination.

Authors:  M Rodriguez; K Pavelko; R L Coffman
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  CD8+ T cells directed against a viral peptide contribute to loss of motor function by disrupting axonal transport in a viral model of fulminant demyelination.

Authors:  Charles L Howe; Daren Ure; Jaimie D Adelson; Reghann LaFrance-Corey; Aaron Johnson; Moses Rodriguez
Journal:  J Neuroimmunol       Date:  2007-05-09       Impact factor: 3.478

10.  Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice.

Authors:  M K Njenga; K D Pavelko; J Baisch; X Lin; C David; J Leibowitz; M Rodriguez
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.